Assay News and Research

RSS

Research confirms benefits of commonly used traditional remedies for a range of illnesses

Research presented to the British Pharmaceutical Conference today, confirms the benefits of commonly used traditional remedies for a range of illnesses, including cancer, offering a scientific justification for their use.

29 Sep 2004

Microfluidics help lab-on-a-chip development skyrocket

Lab-on-a-chip (LOC) development has skyrocketed in the last couple of years due to constant efforts in harnessing microfluidics and µTAS to improve the LOC design and function. The distinct advantages that they bestow on applications are pushing the commercial potential of LOCs.

28 Sep 2004

Study presents multiple lines of evidence against the proposed link between SV40 and human mesotheliomas

Mesothelioma is an aggressive cancer of the chest cavity that kills about 2000 people a year in the United States.

26 Sep 2004

Nanowires could be used to sense thousands of different viruses

Harvard University scientists have found that ultra-thin silicon wires can be used to electrically detect the presence of single viruses, in real time, with near-perfect selectivity.

22 Sep 2004

Further study is needed before link between gastroesophageal reflux disorder and otitis media can be firmly established

Does gastroesophageal reflux disorder (GERD) lead to middle ear infections in young children? Otitis media (OM) or ear infection, has the highest incidence, 62.9 percent, among all medical conditions in children younger than age five. Recent studies have suggested that GERD may cause OM.

18 Sep 2004

Neck surgeons brush up on West Nile virus

Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

17 Sep 2004

Chemotherapy experts refute ASCO recommendations on use of drug sensitivity and resistance assays

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

1 Sep 2004

Chiron acquires a variant Creutzfeldt-Jakob disease research company

Chiron Corporation has announced that it had acquired Prion Solutions Inc., a privately held company based in La Jolla, Calif., focused on research into variant Creutzfeldt-Jakob disease (vCJD) and other prion-related diseases. Financial terms of the acquisition were not disclosed.

1 Sep 2004

Regular exercise boosts immune system in older men

As it turns out, judging by the reaction strength of their immune system to an unknown, but harmless, protein antigen, it’s possible for men over 70 to mount an immune response similar to that produced by much younger men -- if they get regular moderate physical activity of about six hours a week.

25 Aug 2004

Exposure to simian virus 40 (SV40) is not associated with cancer in humans

Two upcoming studies by scientists at the National Cancer Institute (NCI), provide further evidence that exposure to simian virus 40 (SV40) is not associated with cancer in humans.

23 Aug 2004

Nucleic acid-amplification testing has improved the safety of the nation's blood supply

State-of-the-art testing systems to screen donated blood have improved the safety of the nation's blood supply by preventing the transmission of potentially deadly viruses, according to a new study funded by the National Heart, Lung, and Blood Institute.

18 Aug 2004

Scientists discover the body's own defense against H.Pylori, the cause of stomach ulcers and stomach cancer

An international team led by The Burnham Institute's Minoru Fukuda, Ph.D., has discovered that a human glycoprotein inhibits Helicobacter pylori ("H. pylori"), the bacterium that causes stomach ulcers and is linked with 90% of stomach cancers.

13 Aug 2004

Correlation between HCV viral load and severity of liver disease

The significance of hepatitis C virus (HCV) serum titers (HCV viral load) has been examined in several clinical situations. There is much evidence that patients with a lower viral load have better response rates to anti-viral therapy compared to those with higher levels.

9 Aug 2004

Recommendation against the use of chemotherapy sensitivity and resistance assays

A new technology assessment from the American Society of Clinical Oncology states that the use of chemotherapy sensitivity and resistance assays (CSRAs) to select chemotherapeutic agents for cancer patients should not be undertaken outside of the clinical trial setting.

3 Aug 2004

DNA testing of one millionth sheep for scrapie susceptibility

Orchid BioSciences has announced that its animal genetic testing facility in the U.K. has completed DNA testing of its one millionth sheep for scrapie susceptibility.

10 Jul 2004

Chromatin array a new technology for examining DNA

A new technique for examining DNA is giving scientists a more detailed picture of which genes have the propensity for activation, offering a new tool for understanding how genes function and possibly for diagnosing disease.

8 Jul 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Gestational diabetes is a type of diabetes, or high blood sugar, that only pregnant women get

Gestational diabetes is a type of diabetes, or high blood sugar, that only pregnant women get. If a woman is found to have high blood sugar when she's pregnant, but she never had high blood sugar before, she has gestational diabetes.

15 Jun 2004

Proteins transform DNA into molecular velcro

Proteins critical for compacting DNA in preparation for cell division actually interact with the double helix to fashion it into a kind of “molecular Velcro,” researchers have discovered.

5 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004